Look up NLS. They are working with an israeli company on a pan-viral vaccine. if you read the various pr's on the new collaboration as well as GMU furthering it's research on Brilacidin, including pan-corona virus and in vivo testing, as well as other topics noted, it seems NLS would be a benefit. They collaborate with GMU, not IPIX (as per the PR). IPIX would get the benefit of this collaboration IMHO
NLS is a "preclinical" CRO. They handle research up to the point where the device/drug enters clinical trials. Given that, they would NOT be contracted to handle the clinical trial for IPIX.